NCT06975085

Brief Summary

The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
781

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Apr 2025

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 16, 2025

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

May 7, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 16, 2025

Completed
Last Updated

February 12, 2026

Status Verified

February 1, 2026

Enrollment Period

14 days

First QC Date

May 7, 2025

Last Update Submit

February 9, 2026

Conditions

Keywords

breast cancer riskrisk perceptionsscreening intentions

Outcome Measures

Primary Outcomes (3)

  • Risk rejection as measured by a numeric estimate

    Participants are asked whether they agree or disagree with their Gail Model risk estimate. An open text box allows them to write the risk number that they believe is accurate for them.

    at baseline survey

  • Risk-concordant information seeking

    Participants will be given the opportunity to get more information about breast cancer screening, and will be given response options to receive information for women at lower than average risk, higher than average risk, or women with risk that is "about the same as a typical woman". Concordance is measured by agreement between the participants' actual risk estimate and the option that they choose.

    at baseline survey

  • Screening intentions

    Participants are asked: In the next 12 months, do you plan to get a mammogram? The question is answered on a 5-point will-will not Likert scale. 1=definitely will not, 2=probably will not, 3=maybe, 4=probably will, 5=definitely will

    at baseline survey

Study Arms (1)

Breast cancer risk presentation

OTHER

All participants are presented with their personal breast cancer risk, estimated using the Gail Model

Behavioral: Presentation of a personal breast cancer risk estimate

Interventions

Participants answer questions that are used to calculate their personal breast cancer risk using the Gail Model. This risk estimate is presented to participants using written text and an icon array.

Breast cancer risk presentation

Eligibility Criteria

Age39 Years - 74 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female sex
  • Age 39-74 (i.e., people who are eligible for routine breast cancer screening and for whom guidelines recommend an informed, risk-based decision)
  • English literacy
  • Black or African American race

You may not qualify if:

  • \. Prior diagnosis of
  • breast cancer
  • Ductal carcinoma in situ (DCIS)
  • Lobular carcinoma in situ (LCIS)
  • Known BRCA1/2 gene mutation
  • Cowan syndrome
  • Li-Fraumeni syndrome
  • Having received previous chest radiation for treatment of Hodgkin's lymphoma.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Colorado

Aurora, Colorado, 80045, United States

Location

Study Officials

  • Laura D Scherer, PhD

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR
  • Erika Waters, PhD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 7, 2025

First Posted

May 16, 2025

Study Start

April 16, 2025

Primary Completion

April 30, 2025

Study Completion

April 30, 2025

Last Updated

February 12, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

We will share the protocol, code books, and data set associated with this study on the Open Science Framework after ensuring that it is completely anonymized.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
IPD and supporting information will be made available when we submit the first manuscript to a journal for review.
Access Criteria
Anyone will be able to access the IPD and supporting information by downloading it from OSF.
More information

Locations